LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

Home・Aandelen Lijst・Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

424.94 -0.49

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

423.38

Max

429.49

Belangrijke statistieken
By Trading Economics
Inkomsten	108M 1.2B
Verkoop	-240M 3B
K/W Sectorgemiddelde	27.697 49.8
EPS	5.03
Winstmarge	36.909
Werknemers	6,400
EBITDA	-215M 1.1B

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+32.46% upside

Dividenden
By Dow Jones
Volgende Winsten	3 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	977M 109B
Vorige openingsprijs	425.43
Vorige sluitingsprijs	424.94

Nieuwssentiment

By Acuity

92%

5 / 347 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

428.545 / 498.65 Steun & Weerstand

Vertex Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 mei 2026, 20:57 UTC

Winsten

Vertex Pharmaceuticals Posts Higher 1Q Profit

12 feb 2026, 21:47 UTC

Winsten

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

3 nov 2025, 21:44 UTC

Winsten

Vertex Pharmaceuticals Revenue Climbs on Demand for Cystic Fibrosis Drugs

5 aug 2025, 00:05 UTC

Populaire aandelen

Stocks to Watch: Palantir Technologies, Hims & Hers Health, Vertex Pharmaceuticals, Kyndryl

4 aug 2025, 21:21 UTC

Winsten

Belangrijke Marktbewegers

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4 aug 2025, 20:45 UTC

Winsten

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4 mei 2026, 20:02 UTC

Winsten

Vertex Pharmaceuticals Reiterates 2026 Guidance

4 mei 2026, 20:01 UTC

Winsten

Vertex Pharmaceuticals 1Q Net $1.03B >VRTX

4 mei 2026, 20:01 UTC

Winsten

Vertex Pharmaceuticals 1Q Rev $2.99B >VRTX

4 mei 2026, 20:01 UTC

Winsten

Vertex Pharmaceuticals 1Q Adj EPS $4.47 >VRTX

4 mei 2026, 20:01 UTC

Winsten

Vertex Pharmaceuticals 1Q EPS $4.02 >VRTX

12 feb 2026, 21:13 UTC

Winsten

Vertex Pharmaceuticals Guidance Includes Immaterial Cost Impact From Tariffs in 2026 >VRTX

12 feb 2026, 21:13 UTC

Winsten

Vertex Pharmaceuticals Sees FY26 Rev $12.95B-$13.1B >VRTX

12 feb 2026, 21:01 UTC

Winsten

Vertex Pharmaceuticals 4Q Rev $3.19B >VRTX

12 feb 2026, 21:01 UTC

Winsten

Vertex Pharmaceuticals 4Q Net $1.19B >VRTX

12 feb 2026, 21:01 UTC

Winsten

Vertex Pharmaceuticals 4Q EPS $4.65 >VRTX

12 feb 2026, 21:01 UTC

Winsten

Vertex Pharmaceuticals 4Q Adj EPS $5.03 >VRTX

3 nov 2025, 21:05 UTC

Winsten

Vertex Pharmaceutic Sees 2025 Rev $11.9B-$12B >VRTX

3 nov 2025, 21:02 UTC

Winsten

Vertex Pharmaceuticals 3Q EPS $4.20 >VRTX

3 nov 2025, 21:02 UTC

Winsten

Vertex Pharmaceuticals 3Q Adj EPS $4.80 >VRTX

3 nov 2025, 21:02 UTC

Winsten

Vertex Pharmaceuticals 3Q Net $1.08B >VRTX

3 nov 2025, 21:02 UTC

Winsten

Vertex Pharmaceuticals 3Q Rev $3.08B >VRTX

5 aug 2025, 20:44 UTC

Winsten

These Stocks Moved the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5 aug 2025, 18:17 UTC

Winsten

These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5 aug 2025, 15:25 UTC

Winsten

Correction to These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Caterpillar, BP, and More -- Barrons.com

5 aug 2025, 14:12 UTC

Winsten

Vertex Stock Tumbles After Strong Earnings. What's Spooking Investors. -- Barrons.com

5 aug 2025, 11:27 UTC

Winsten

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 aug 2025, 10:55 UTC

Winsten

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 aug 2025, 10:36 UTC

Winsten

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 aug 2025, 10:18 UTC

Winsten

Vertex Stock Tumbles 15% After Strong Earnings. What's Spooking Investors. -- Barrons.com

Peer Vergelijking

Prijswijziging

Vertex Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

32.46% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 566.48 USD 32.46%

Hoogste 641 USD

Laagste 436 USD

Gebaseerd op 24 Wall Street-analisten die 12-maands prijsdoelen bieden voor Vertex Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

24 ratings

Buy

Hold

Sell

Gebaseerd op 24 analisten die aandelenratings hebben gegeven aan Vertex Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

428.545 / 498.65Steun & Weerstand

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

5 / 347 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.